Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety study of AVAXIM 160U hepatitis A vaccine in routine practice
2016-001964-13Phase 4
- Sponsor
- Sanofi
- Start
- May 2016
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hepatitis A vaccine inactivated in hepatitis A (HAV), sponsored by Sanofi. Primary endpoint: Safety profile (solicited and unsolicited adverse events).
02
Drugs
hepatitis A vaccine inactivated
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on 2016-001964-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001964-13.